Severe asthma is associated with an increased risk for exacerbations, reduced lung
function, fixed airflow obstruction, and substantial morbidity and mortality. The concept of …

The epithelial barriers of the skin, gut, and respiratory tract are critical interfaces between the
environment and the host, and they orchestrate both homeostatic and pathogenic immune …

Background Stepwise intensification of inhaled corticosteroids (ICS) is routine for severe
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …

Background Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's
overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data …

The advent of personalized medicine has revolutionized the whole approach to the
management of asthma, representing the essential basis for future developments. The …

Over the past years, eosinophils have become a focus of scientific interest, especially in the
context of their recently uncovered functions (eg antiviral, anti‐inflammatory, regulatory) …

Severe asthma is associated with significant morbidity and mortality despite the maximal use
of inhaled corticosteroids and additional controller medications, and has a high economic …

Asthma is a common and heterogeneous disease characterized by lower airway
inflammation and airflow limitation. Critical factors in asthma management include …

Biologics or molecularly targeted drugs are often highly effective for the treatment of allergic
diseases and other immunologic disorders, and they are relatively safe for short-term use as …

Asthma is now recognized as a heterogeneous disease, encompassing different
phenotypes driven by distinct pathophysiological mechanisms called endotypes. Common …